Analogs of pituitary adenylate cyclase-activating polypeptide (PACAP) and methods for their use
US8916517B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Nov 2, 2010 |
| Grant date | Dec 23, 2014 |
| Priority date | — |
| Expiry date | Nov 2, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/50
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to novel analogs of pituitary adenylate cyclase-activating polypeptide (PACAP), which are agonists for the PACAP/vasoactive intestinal peptide (VIP) receptors: PAC1, VPAC1 and VPAC2 receptors. These PACAP analogs can be used as prophylactic/therapeutic agents for a wide range of medical disorders, including (but not limited to) cancer and autoimmune disease. These PACAP analogs can be coupled to suitable radionuclides and used in the localization, diagnosis and treatment of disseminated cancers and metastatic tumors, or coupled to small molecule therapeutics and used as vectors for targeted drug delivery. This invention also provides pharmaceutical compositions of one or more PACAP-like compounds of the invention either alone or in combination with one or more other prophylactic/therapeutic agents.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.